宜宾开双眼皮内眼角宜宾哪里激光脱毛好,宜宾埋线双眼皮过程,宜宾嘴部脱毛价格,宜宾打针能祛眼袋吗,宜宾 激光脱毛,宜宾隆鼻改善短鼻的价格,宜宾脂肪注射丰胸多少钱

WASHINGTON, Nov. 24 (Xinhua) -- An inexpensive drug that treats Type 2 diabetes has been shown to prevent a number of natural and man-made chemicals from stimulating the growth of breast cancer cells, according to a newly published study by a Michigan State University researcher. The research, led by pediatrics professor James Trosko and colleagues from South Korea's Seoul National University, provides biological evidence for previously reported epidemiological surveys that long-term use of the drug metformin for Type 2 diabetes reduces the risk of diabetes-associated cancers, such as breast cancers.The research appeared online this week in PLoS One.For the study, Trosko and colleagues focused on the concept that cancers originate from adult human stem cells and that there are many natural and man-made chemicals that enhance the growth of breast cancer cells. Using culture dishes, they grew miniature human breast tumors, or mammospheres, that activated a certain stem cell gene. Then the mammospheres were exposed to natural estrogen -- a known growth factor and potential breast tumor promoter -- and man-made chemicals that are known to promote tumors or disrupt the endocrine system.The team found that estrogen and the chemicals caused the mammospheres to increase in numbers and size. However, with metformin added, the numbers and size of the mammospheres were dramatically reduced. While each of the chemicals enhanced growth by different means, metformin seemed to be able to inhibit their stimulated growth in all cases."While future studies are needed to understand the exact mechanism by which metformin works to reduce the growth of breast cancers, this study reveals the need to determine if the drug might be used as a preventive drug and for individuals who have no indication of any existing cancers," Trosko said.

WASHINGTON, Dec. 21 (Xinhua) -- New research suggests that, in people who don't currently have memory problems, those with smaller regions of the brain's cortex may be more likely to develop symptoms consistent with very early Alzheimer's disease.The study was published Wednesday in the online issue of Neurology, the medical journal of the American Academy of Neurology.For the study, researchers used brain scans to measure the thickness of regions of the brain's cortex in 159 people free of dementia with an average age of 76. The brain regions were chosen based on prior studies showing that they shrink in patients with Alzheimer's dementia.Of the 159 people, 19 were classified as at high risk for having early Alzheimer's disease due to smaller size of particular regions known to be vulnerable to Alzheimer's in the brain's cortex, 116 were classified as average risk and 24 as low risk. At the beginning of the study, participants were also given tests that measured memory, problem solving and ability to plan and pay attention. The tests will go on over the next three yearsThe study found that 21 percent of those at high risk experienced cognitive decline during three years of follow-up after the MRI scan, compared to seven percent of those at average risk and none of those at low risk."Further research is needed on how using MRI scans to measure the size of different brain regions in combination with other tests may help identify people at the greatest risk of developing early Alzheimer's as early as possible," said study author Bradford Dickerson, of Massachusetts General Hospital in Boston and a member of the American Academy of Neurology.

ALMATY, Nov. 4 (Xinhua) -- Kazakhstan's Center for Prevention and Control of AIDS said Friday that the country had 17,266 registered HIV carriers as of Oct. 1,compared with 15,908 as of Feb. 1, 2010.Of the HIV-positive people, 1,432 were diagnosed with AIDS while 1,110 people carrying the virus AIDS have died, the center said.Last year, it said, a total of 1,969 new HIV cases were reported in the country.

MOSCOW, Oct. 24 (Xinhua) -- The Russian Space Agency Roscosmos confirmed on Monday the list of next crew members who will fly to the International Space Station (ISS) on Nov. 14.Russia's Soyuz TMA-22 spacecraft will bring Russian cosmonauts Anton Shkaplerov and Anatoly Ivanishin and American astronaut Daniel Burbank to the ISS for a 124-day-long mission.Russia's Gennady Padalka and Sergei Revin and American Josef Akaba are announced as the backup crew.According to the Roscosmos, the new crew will host one manned and three unmanned cargo ships during their stay in the ISS and conduct a space walk as well as 37 scientific experiments.During the new crew's stay, the ISS would also make its 75,000th revolution around the Earth, the Roscosmos said.The launch of the Soyuz TMA-22 was initially scheduled on Sept. 22, but was postponed after the failed launch of the Progress cargo ship to the ISS on Aug. 24.